Literature DB >> 31385238

Identifying miltefosine-resistant key genes in protein-protein interactions network and experimental verification in Iranian Leishmania major.

Niloofar Lari1, Razieh Jalal2,3, Zarrin Minuchehr4, Majid Rajabian Noghondar1.   

Abstract

Drug resistance is a complex phenomenon during leishmaniasis chemotherapy. In this study, the genes and pathways involved in miltefosine (MIL)-resistant Leishmania were identified using microarray data and in silico approaches. GSE30685 and GSE45496 were obtained from GEO database and analyzed with GEO2R tool to identify genes involved in MIL-resistant Leishmania. 177 differentially expressed genes (DEGs) were selected from these GSEs, which about half of them were uncharacterized/hypothetical proteins. The interactions between DEGs were investigated using STRING database and protein-protein interaction (PPI) networks. Five hub nodes were found in the PPI network. The gene ontology (GO) analysis of the resulting network revealed that DNA replication (GO:0006260) and ATP hydrolysis coupled proton transport (GO:0015991) were the most enriched GO term. Iranian MIL-resistant Leishmania major (L. major) parasites were generated by exposure of wild-type isolates to the increasing concentrations of MIL over a period of 5 months. Proof of mRNA expression levels of the obtained hub genes was assessed in Iranian wild-type and acquired resistant L. major parasites by real-time PCR. A significant higher expression level of LDBPK_150170 (encoding protein phosphatase 2C, PP2C), was only observed in Iranian L. major parasites resistance to MIL. Moreover, the RT-PCR results showed that the expression of metacyclic marker (small hydrophilic endoplasmic reticulum-associated protein, SHERP) and MIL-resistant marker (Leishmania MIL-transporter, LMT) was significantly increased and decreased, respectively, in Iranian MIL-resistant L. major parasites. Taken together, these data suggested that PP2C as well as SHERP and LMT genes may be prospective targets for the treatment of MIL-resistant Leishmania.

Entities:  

Keywords:  Acquired MIL-resistant Leishmania; Differentially expressed genes; Gene expression omnibus; Protein–protein interaction network

Mesh:

Substances:

Year:  2019        PMID: 31385238     DOI: 10.1007/s11033-019-04992-4

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  63 in total

1.  Short-course of oral miltefosine for treatment of visceral leishmaniasis.

Authors:  S Sundar; A Makharia; D K More; G Agrawal; A Voss; C Fischer; P Bachmann; H W Murray
Journal:  Clin Infect Dis       Date:  2000-10       Impact factor: 9.079

2.  Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic.

Authors:  S Sundar; D K More; M K Singh; V P Singh; S Sharma; A Makharia; P C Kumar; H W Murray
Journal:  Clin Infect Dis       Date:  2000-10       Impact factor: 9.079

3.  Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent.

Authors:  J Soto; J Toledo; P Gutierrez; R S Nicholls; J Padilla; J Engel; C Fischer; A Voss; J Berman
Journal:  Clin Infect Dis       Date:  2001-09-05       Impact factor: 9.079

4.  American tegumentary leishmaniasis: Is antimonial treatment outcome related to parasite drug susceptibility?

Authors:  Vanessa Yardley; Nimer Ortuno; Alejandro Llanos-Cuentas; Francois Chappuis; Simonne De Doncker; Luis Ramirez; Simon Croft; Jorge Arevalo; Vanessa Adaui; Hernan Bermudez; Saskia Decuypere; Jean-Claude Dujardin
Journal:  J Infect Dis       Date:  2006-09-08       Impact factor: 5.226

5.  Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance.

Authors:  F Javier Pérez-Victoria; Francisco Gamarro; Marc Ouellette; Santiago Castanys
Journal:  J Biol Chem       Date:  2003-09-27       Impact factor: 5.157

Review 6.  Clinical aspects of visceral leishmaniasis in HIV infection.

Authors:  Joseph N Jarvis; Diana N Lockwood
Journal:  Curr Opin Infect Dis       Date:  2013-02       Impact factor: 4.915

7.  Leishmaniasis Vaccine: Where are We Today?

Authors:  Lukasz Kedzierski
Journal:  J Glob Infect Dis       Date:  2010-05

8.  Phlebotomine Sand Flies (Diptera: Psychodidae) in Iran and their Role on Leishmania Transmission.

Authors:  Mr Yaghoobi-Ershadi
Journal:  J Arthropod Borne Dis       Date:  2012-06-30       Impact factor: 1.198

9.  Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites.

Authors:  Ramtin Hadighi; Mehdi Mohebali; Patrick Boucher; Homa Hajjaran; Ali Khamesipour; Marc Ouellette
Journal:  PLoS Med       Date:  2006-04-18       Impact factor: 11.069

10.  High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia.

Authors:  Ermias Diro; Lutgarde Lynen; Rezika Mohammed; Marleen Boelaert; Asrat Hailu; Johan van Griensven
Journal:  PLoS Negl Trop Dis       Date:  2014-05-22
View more
  2 in total

Review 1.  Parasite protein phosphatases: biological function, virulence, and host immune evasion.

Authors:  Jenny Nancy Gómez-Sandoval; Alma Reyna Escalona-Montaño; Abril Navarrete-Mena; M Magdalena Aguirre-García
Journal:  Parasitol Res       Date:  2021-07-26       Impact factor: 2.289

2.  An immunoinformatic approach driven by experimental proteomics: in silico design of a subunit candidate vaccine targeting secretory proteins of Leishmania donovani amastigotes.

Authors:  Md Anik Ashfaq Khan; Jenifar Quaiyum Ami; Khaledul Faisal; Rajashree Chowdhury; Prakash Ghosh; Faria Hossain; Ahmed Abd El Wahed; Dinesh Mondal
Journal:  Parasit Vectors       Date:  2020-04-15       Impact factor: 3.876

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.